



**Proteomics International**

LABORATORIES LTD

**ASX Release**

**16 April 2018**

**ASX code: PIQ**

## **Secondary Trading Notice**

Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ) has today issued 1,709,041 fully paid ordinary shares (**Shares**) upon the exercise of the remaining quoted options exercisable at \$0.20 per option that were not exercised by 31 March 2018 (**Unexercised PIQO Options**) raising \$341,808.

The Shares on conversion of the Unexercised PIQO Options were allocated to the underwriter in accordance with the underwriting agreement announced to the ASX on 14 March 2018 and the Company has issued the Shares in accordance with ASX Listing Rule 7.2 (exception 12).

### **Secondary Trading Notice Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 ("Act")**

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Shares noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

- (a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- (c) as at the date of this Notice, there is no information:
  - (i) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  - (ii) that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
    - a. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - b. the rights and liabilities attaching to the relevant Shares.

Proteomics International remains engaged with a number of potential strategic partners to bring the Promarker™ technology to market in Australia and overseas. It is possible that announcements may be made in the foreseeable future which could influence the price of PIQ Shares.

ENDS

### **For further information please contact:**

Karen Logan  
Company Secretary  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)